News about 'cptr'

Tuberculosis Drug Development: Towards a Critical Path for Developing New Regimes to Treat Tuberculosis Volume 211 suppl 3 June 15, 2015 Click here for access to supplement Articles: Eric Nuermberger and Debra Hanna Assessing the Landscape of Tools and Approaches for Novel Tuberculosis Regimen...

Click to access links and audio from Lancet ID TB Edition Executive Summary To commemorate World TB Day 2013, The Lancet Infectious Diseases publishes a Series of papers on tuberculosis, a disease that has long plagued human beings and was declared a global emergency in 1993 by WHO. Without...

Click here to read the full document. Launch of the Good Participatory Practice Guidelines for TB Drug Trials The Stakeholder and Community Engagement Workgroup of the Critical Path to TB Drug Regimens initiative launches guidelines that will facilitate the involvement of communities and...

The audience takes in the promise of the NC--002 trial. During the “Cure All: A briefing on the status of the most promising new TB drugs research” sponsored by the Critical Path to New TB Drug Regimens (CPTR) on Monday, March 19, Dr. Mel Spigelman, CEO & President, of TB Alliance announced the...

On November 17 and 18, a TB Clinical Trials Consultants Meeting was held at St. George’s, University of London. The meeting was organized by CDC , CPTR , INTERTB , NIH , and TB Alliance . The meeting was convened to catalog expert opinion on the conduct of Phase 2 and Phase 3 clinical trials in...

SABC Story on NC001 The clinical trial of the first novel regimen was featured today on SABC TV in South Africa. This is the first clinical trial to test multiple new TB drugs in combination; the trial is known as New Combination 1 (NC001). The experimental regimen undergoing testing in this trial...

NC001 Today, the TB Alliance announced the first clinical trial to test multiple new TB drugs in combination; the trial is known as New Combination 1 (NC001).The experimental regimen undergoing testing in this trial consists of experimental TB drugs PA-824, Moxifloxacin, and Pyrazinamide, an...

2.1 Å DNA gyrase complex with GSK299423 (Figure 2 from paper) This week we reposted an article from DailyFinance.com regarding a new antibactierial compound from GlaxoSmithKline (GSK) . GSK has recently published a Nature paper describing the 2.1 angstom crystal structure of Staphylococcus aureus...

CPTR could deliver a new TB regimen in just 6 years as opposed to 24 After a decades-long drought, new pharmaceutical discoveries and repurposing of existing antimicrobials have produced about 10 drugs from 7 different classes which are now in various stages of clinical development for TB. Many...

Today marks the launch of an exciting new initiative in TB R&D. The US Food and Drug Administration (FDA) has supported the Critical Path to TB Drug Regimens (CPTR). The CPTR comprises a broad collaborative network of partners including pharmaceutical companies, government, academia, and...